{"id":"dwj1507","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available information on DWJ1507's molecular target or mechanism, the precise biological pathway cannot be described. Phase 3 status indicates the drug has demonstrated sufficient efficacy and safety in phase 2 trials to warrant late-stage clinical evaluation, but detailed mechanistic data may remain proprietary or under regulatory review.","oneSentence":"DWJ1507 is an investigational therapeutic agent in phase 3 development by Daewoong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:21.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04772443","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-02","conditions":"Dyslipidemias","enrollment":280}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DWJ1507","genericName":"DWJ1507","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}